Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes

Clinical Infectious Diseases

Volumn 69, Issue 7, 2019, Pages 1218-1225

  Self, Wesley H ^a   Wunderink, Richard G ^b   Dinubile, Mark J ^c   Stossel, Thomas P ^c   Levinson, Susan L ^c   Williams, Derek J ^a   Anderson, Evan J ^d   Bramley, Anna M ^e   Jain, Seema ^e   Edwards, Kathryn M ^a   Grijalva, Carlos G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BioAegis Therapeutics   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antimicrobial resistance; plasma gelsolin; pneumonia

Indexed keywords

GELSOLIN; HYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DEATH; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOBACTERIUM; OBSERVATIONAL STUDY; PLASMA VOLUME; PNEUMOCYSTIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VERY ELDERLY; VIRUS DETECTION; VIRUS PNEUMONIA; ANTIBIOTIC RESISTANCE; BLOOD; COMMUNITY ACQUIRED INFECTION; OUTCOME ASSESSMENT; PNEUMONIA; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FEMALE; GELSOLIN; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT OUTCOME ASSESSMENT; PNEUMONIA; PROGNOSIS; YOUNG ADULT;

EID: 85068155707     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy1049     Document Type: Article

References (41)

1. Ramirez JA, Wiemken TL, Peyrani P, et al. University of Louisville Pneumonia Study: adults hospitalized with pneumonia in the United States: incidence, epide-miology, and mortality. Clin Infect Dis 2017; 65: 1806-12.
2. Global Burden of Disease Study. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17: 1133-61.
3. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415-27.
4. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 2002; 162:1059-64.
5. Ho PL, Cheng VC, Chu CM. Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 2009; 136:1119-27.
6. Wunderink RG, Mandell L. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33:311-8.
7. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin tox-icity. N Engl J Med 1992; 326:1335-41.
8. DiNubile MJ. Plasma gelsolin: in search of its raison d'etre. Am J Physiol Cell Physiol 2007; 292: C1240-2.
9. Hartwig JH, Chambers KA, Stossel T P. Association of gelsolin with actin filaments and cell membranes of macrophages and platelets. J Cell Biol 1989; 108:467-79.
10. Vasconcellos CA, Lind SE. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood 1993; 82:3648-57.
11. Smith DB, Janmey PA, Sherwood JA, Howard RJ, Lind SE. Decreased plasma gel-solin levels in patients with Plasmodium falciparum malaria: a consequence of hemolysis? Blood 1988; 72:214-8.
12. Erukhimov JA, Tang ZL, Johnson BA, et al. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Resp Crit Care Med 2000; 162:288-94.
13. Ordija C, Chiou T T, Yang Z, Deloid GM, de Oliveira Valdo M, et al. Free actin impairs macrophage bacterial defenses via scavenger receptor MARCO interaction, with reversal by plasma gelsolin. Am J Physiol Lung Cell Mol Physiol 2017; 312: L1018-028.
14. Goetzl EJ, Lee H, Azuma T, Stossel T P, Turck C W, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 2000; 275:14573-8.
15. Osborn TM, Dahlgren C, Hartwig JH, Stossel T P. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gel-solin. Am J Physiol Cell Physiol 2007; 292:C1323-30.
16. Bucki R, Kulakowska A, Byfield F, et al. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol Cell Physiol 2010; 299:C1516-23.
17. Yang Z, Chiou T T, Stossel T P, Kobzik L. Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. Am J Physiol Lung Cell Mol Physiol 2015; 309:L11-6.
18. Bucki R, Georges PC, Espinassous Q, et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005; 44:9590-7.
19. Bucki R, Byfield F, Kulakowska A, et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall compo-nents. J Immunol 2008; 181:4936-44.
20. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28:738-45.
21. Bucki R, Durnas B, Watek M, et al. Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics. Infect Drug Resist 2018; 11: 77-86.
22. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160:1673-81.
23. Lee PS, Drager LR, Stossel T P, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 2006; 243:399-403.
24. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 2002; 180: 91-104.
25. Lind SE, Smith DB, Janmey PA, Stossel T P. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 1988; 138:429-34.
26. Smith DB, Janmey PA, Lind SE. Circulating actin-gelsolin complexes following oleic acid-induced lung injury. Am J Pathol 1988; 130:261-7.
27. Li M, Cui F, Cheng Y, et al. Gelsolin: role of a functional protein in mitigating radiation injury. Cell Biochem Biophys 2015; 71:389-96.
28. Lee PS, Waxman AB, Cotich KL, Chung S W, Perrella MA, Stossel T P. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007; 35:849-55.
29. Wang H, Cheng B, Chen Q, et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care 2008; 12:R106.
30. Huang LF, Yao YM, Li J F, et al. Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients. PLoS One 2011; 6:e25748.
31. Xu JF, Liu WG, Dong XQ, Yang SB, Fan J. Change in plasma gelsolin level after traumatic brain injury. J Trauma Acute Care Surg 2012; 72:491-6.
32. Chou SH, Lee PS, Konigsberg RG, et al. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke 2011; 42:3624-7.
33. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 2002; 50: 54-60.
34. Kaneva MK, Greco K V, Headland SE, et al. Identification of novel chondroprotective mediators in resolving inflammatory exudates. J Immunol 2017;198: 2876-85.
35. Piktel E, Levental I, Durnas B, Janmey PA, Bucki R. Plasma gelsolin: indicator of inflammation and its potential as a diagnostic tool and therapeutic target. Int J Mol Sci 2018; 19: 2516.
36. Rothenbach PA, Dahl B, Schwartz J, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 2004; 96:25-31.
37. Yang Z, Levinson S, Stossel T, DiNubile MJ, Kobzik L. Delayed therapy with plasma gelsolin improves survival in murine pneumococcal pneumonia [Abstract]. Open Forum Infect Dis 2017; 4 (Suppl 1): S474-5.
38. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
39. Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375-84.
40. Self WH, Grijalva CG, Williams DJ, et al. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with communi-ty-acquired pneumonia. Chest 2016; 150:819-28.
41. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression and survival analysis. New York: Springer; 2001.